Wells Fargo’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-136,814
| Closed | -$2.77M | – | 7866 |
|
|
2022
Q4 | $2.77M | Sell |
136,814
-68,303
| -33% | -$1.05M | ﹤0.01% | 2525 |
|
|
2022
Q3 | $2.21M | Buy |
205,117
+1,886
| +0.9% | +$21.4K | ﹤0.01% | 2652 |
|
|
2022
Q2 | $2.44M | Sell |
203,231
-1,995
| -1% | -$32.2K | ﹤0.01% | 2632 |
|
|
2022
Q1 | $4.4M | Sell |
205,226
-19,071
| -9% | -$505K | ﹤0.01% | 2562 |
|
|
2021
Q4 | $7.54M | Sell |
224,297
-23,195
| -9% | -$646K | ﹤0.01% | 2127 |
|
|
2021
Q3 | $6.37M | Sell |
247,492
-3,515
| -1% | -$62.8K | ﹤0.01% | 2611 |
|
|
2021
Q2 | $3.36M | Buy |
251,007
+925
| +0.4% | +$11.4K | ﹤0.01% | 3231 |
|
|
2021
Q1 | $2.66M | Sell |
250,082
-2,123
| -0.8% | -$24.2K | ﹤0.01% | 3446 |
|
|
2020
Q4 | $2.02M | Buy |
252,205
+45,255
| +22% | +$356K | ﹤0.01% | 3490 |
|
|
2020
Q3 | $1.55M | Buy |
206,950
+95,414
| +86% | +$847K | ﹤0.01% | 3514 |
|
|
2020
Q2 | $1.01M | Buy |
111,536
+107,715
| +2,819% | +$1.12M | ﹤0.01% | 3812 |
|
|
2020
Q1 | $36K | Buy |
3,821
+21
| +0.6% | +$251 | ﹤0.01% | 5450 |
|
|
2019
Q4 | $55K | Hold |
3,800
| – | – | ﹤0.01% | 5490 |
|
|
2019
Q3 | $57K | Hold |
3,800
| – | – | ﹤0.01% | 5529 |
|
|
2019
Q2 | $50K | Hold |
3,800
| – | – | ﹤0.01% | 5550 |
|
|
2019
Q1 | $50K | Hold |
3,800
| – | – | ﹤0.01% | 5320 |
|
|
2018
Q4 | $55K | Buy |
3,800
+3,000
| +375% | +$48.9K | ﹤0.01% | 5486 |
|
|
2018
Q3 | $14K | Buy |
800
+700
| +700% | +$12.1K | ﹤0.01% | 5918 |
|
|
2018
Q2 | $1K | Hold |
100
| – | – | ﹤0.01% | 6276 |
|
|
2018
Q1 | $2K | Sell |
100
-225
| -69% | -$4.86K | ﹤0.01% | 6223 |
|
|
2017
Q4 | $7K | Hold |
325
| – | – | ﹤0.01% | 6004 |
|
|
2017
Q3 | $12K | Buy |
+325
| New | +$12.1K | ﹤0.01% | 5842 |
|
Wells Fargo's OPNT Position: Q1 2023 in Review
Wells Fargo sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q1 2023, closing a stake of 136,814 shares — an estimated $2.77M sold.
Wells Fargo first reported a position in OPNT in Q3 2017 and held it in 22 quarters. The position peaked at $7.54M in Q4 2021. 0 funds tracked by Wall St. Rank hold OPNT as of Q1 2023.
- Wells Fargo reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
- Wells Fargo sold 136,814 Opiant Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $2.77M.
- Wells Fargo first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 22 quarters.
- Wells Fargo's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $7.54M in Q4 2021.
- 0 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q1 2023.
Based on Wells Fargo's 13F filing for Q1 2023, filed 12 May 2023.